ENTITY

SIGA Technologies (SIGA US)

18
Analysis
Health CareUnited States
SIGA Technologies, Inc. operates as a commercial-stage pharmaceutical company. The Company offers oral formulation of an antiviral drug for the treatment of human smallpox disease caused by variola virus.
more
Refresh
03 Oct 2022 19:03Issuer-paid

SIGA Technologies - Second contract win from the US DoD in 2022

SIGA Technologies has announced a second procurement contract worth up to $10.7m from the US Department of Defense (DoD) for the procurement of...

Share
27 Sep 2022 19:00Issuer-paid

SIGA Technologies - Monkeypox concern drives international TPOXX win

SIGA Technologies (SIGA) has announced receipt of $16m of international procurement orders in the European Union (EU) and the Asia-Pacific region...

Share
26 Sep 2022 19:04Issuer-paid

SIGA Technologies - Monkeypox likely here to stay

With approximately 64k global cases, monkeypox has become a growing concern and is less transient than initially acknowledged. We expect SIGA...

Share
11 Aug 2022 15:34Issuer-paid

SIGA Technologies - BARDA exercises first option for IV TPOXX

Following strong Q222 results, SIGA Technologies has announced that the Biomedical Advanced Research and Development Authority (BARDA) has...

Share
x